Skip to main content
Top
Published in: Rheumatology International 11/2009

01-09-2009 | Original Paper

Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis

Authors: Xinwei Wang, Zhiming Lin, Qiujing Wei, Yingjuan Jiang, Jieruo Gu

Published in: Rheumatology International | Issue 11/2009

Login to get access

Abstract

The objective of this study was to investigate the expression of IL-23 and IL-17 and the influence of IL-23 on IL-17 production in ankylosing spondylitis (AS) patients. IL-23 and IL-17 levels in the serum and supernatants of cultured peripheral blood mononuclear cells (PBMCs) were determined by ELISA. IL-23p19 mRNA expression in PBMCs were analyzed using RT-PCR. The patients with AS at active stage showed elevated levels of IL-23 and IL-17 in the serum and supernatants of cultured PBMCs. A higher expression of IL-23p19 mRNA in PBMCs of AS patients was also observed. A significantly enhanced production of IL-17 in the supernatants of cultured PBMCs was found in the presence of recombinant IL-23 and this effect was more significant in patients with AS. The results suggest that IL-23 and IL-17 may play critical roles in the pathogenesis of AS and IL-23-stimulated production of IL-17 by PBMCs may be responsible for the development of AS.
Literature
3.
go back to reference Pirhonen J, Matikainen S, Julkunen I (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 169:5673–5678PubMed Pirhonen J, Matikainen S, Julkunen I (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 169:5673–5678PubMed
4.
6.
9.
go back to reference Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352. doi:10.1172/JCI5703 PubMedCrossRef Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352. doi:10.​1172/​JCI5703 PubMedCrossRef
18.
go back to reference Chen Y, Langrish CL, McKenzie BS et al (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116:1317–1326. doi:10.1172/JCI25308 PubMedCrossRef Chen Y, Langrish CL, McKenzie BS et al (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116:1317–1326. doi:10.​1172/​JCI25308 PubMedCrossRef
19.
go back to reference Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177PubMed Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177PubMed
20.
go back to reference Lubberts E, Koenders MI, Oppers-Walgreen B et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659. doi:10.1002/art.20001 PubMedCrossRef Lubberts E, Koenders MI, Oppers-Walgreen B et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659. doi:10.​1002/​art.​20001 PubMedCrossRef
22.
27.
go back to reference Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914. doi:10.1074/jbc.M207577200 PubMedCrossRef Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914. doi:10.​1074/​jbc.​M207577200 PubMedCrossRef
Metadata
Title
Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis
Authors
Xinwei Wang
Zhiming Lin
Qiujing Wei
Yingjuan Jiang
Jieruo Gu
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0883-x

Other articles of this Issue 11/2009

Rheumatology International 11/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.